Farmacosmo SpA

Farmacosmo's capital structure reveals a debt-to-equity ratio of 0.69, indicating moderate leverage relative to equity [doc:HA-latest]. The company's liquidity position is weak, with only 26,080 EUR in cash and equivalents against 7,281,690 EUR in long-term debt [doc:HA-latest]. The current ratio of 1.44 suggests the company can cover its short-term liabilities, but the negative operating and free cash flows of -2,133,360 EUR and -1,670,180 EUR, respectively, highlight ongoing cash generation challenges [doc:HA-latest]. Profitability metrics are deeply negative, with a return on equity of -28.08% and a return on assets of -9.63%, both significantly below the cohort median for the Department Stores industry [doc:HA-latest]. The company reported a net loss of 2,972,060 EUR and an operating loss of 2,279,520 EUR, indicating a failure to achieve profitability despite revenue of 63,003,340 EUR [doc:HA-latest]. Geographically, Farmacosmo is entirely concentrated in Italy, with no disclosed international operations or revenue diversification. This single-market exposure increases vulnerability to domestic economic shifts and regulatory changes [doc:HA-latest]. The company's product portfolio spans 15 categories, including pharmaceuticals, vitamins, and beauty products, but no segment-specific revenue breakdown is available to assess performance drivers [doc:HA-latest]. The company's growth trajectory is uncertain, with a reported revenue of 63,003,340 EUR in the latest period, slightly below the analyst estimate of 64,256,000 EUR [doc:]. The negative net income and operating income suggest no clear path to profitability in the near term. Analysts project a mean EBIT of 2,800,000 EUR for the next period, but this remains unproven given the current financial performance [doc:]. Risk factors include liquidity constraints and the absence of positive cash flows, with a risk assessment rating of medium for liquidity and low for dilution [doc:HA-latest]. The company's capital expenditure of -1,230,890 EUR indicates ongoing investment, but without clear returns, this could exacerbate cash flow issues. No dilution sources are identified in the latest filings, but the low dilution risk rating suggests no immediate pressure from share issuance [doc:HA-latest]. Recent events include the authorization by the Italian Ministry of Health to operate as an online pharmacy, a key enabler of its business model [doc:HA-latest]. No recent filings or transcripts disclose material changes in strategy or operations, and the company's financial performance remains a concern for stakeholders [doc:HA-latest].